Cell therapy (Stem-cell derived) · Immune activation · developed by Mesoblast
Remestemcel-L-rknd is an allogeneic cell therapy made of ex-vivo cultured adult human bone marrow-derived mesenchymal stromal cells. It is thought to act through immunomodulation, inhibiting T cell activation and pro-inflammatory cytokine secretion. It is studied in graft-versus-host disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 11, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07568535 | Phase 3 | GVHD - Graft-Versus-Host Disease | Not yet recruiting | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
GVHD - Graft-Versus-Host Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →